Nvidia Stock Faces Critical Warning Sign. Is the AI Trade Breaking?

BeInCrypto2026/10/09 03:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nvidia stock fell 2.94% Thursday after OpenAI told investors its annualized revenue is roughly $50 billion, about $18 billion below the $68 billion widely reported last month. Alex Kantrowitz, founder of Big Technology, called the gap largely an accounting issue on CNBCs Closing Bell. Nvidia still closed at $230.48, about 5% below its Tuesday record high of $243.37. Why Is Nvidia Stock Taking the Hit for OpenAIs Number? Nvidia and Advanced Micro Devices (AMD) have each signed multibillion-dollar partnerships with OpenAI. Therefore, both chipmakers carry direct exposure to its growth. AMD slid 3.9% the same day. Oracle fell more than 5% in an OpenAI-linked stock crash. The interlinking between AI companies is showing as a number of stocks feel the impact of this issue. Source: Trading View Kantrowitz noted that both stocks have mostly performed well this year. Yahoo Finance data shows Nvidia up about 24%, with a market value near $5.6 trillion. Still, the fundamentals remain strong. Nvidia posted $96.22 billion in revenue last quarter, beating the $92.16 billion estimate, Google Finance data shows. However, Kantrowitz sees skittishness around the AI trade. He said some companies have shifted part of their spending to standard models rather than frontier ones. Can Nvidia Hold If OpenAI or Anthropic Stumbles? Kantrowitz said market breadth is weak, with the top seven stocks outpacing the other 493 in the SP 500. Meanwhile, a Closing Bell host put the tech trade at more than 40% of the market. Kantrowitz agreed the broader market hinges on OpenAI and Anthropic. In contrast, Wedbush analyst Dan Ives named Nvidia among his top five tech picks for 2027. He argued investors underestimate a $4 trillion AI spending wave. Kantrowitz expects Anthropics initial public offering (IPO) within weeks, most likely, and OpenAIs next year. The market is waiting for something to go wrong, he said, and any wrinkle could repeat Thursdays selloff or worse. Kantrowitz said Anthropics leaked S-1, a US listing filing, showed losses outpacing revenue gains. With two IPOs expected, filings could show whether AI revenue can carry the spending behind Nvidias valuation. Read the article at BeInCrypto

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53